Latest Close
₹351.90
+5.85%
Connecting…
Day Range
-
Full OHLC pending
Volume
-
Full session data pending
50 DMA
₹402.08
200 DMA
₹394.42
1 year gain / loss
−₹24.70(-6.56%)
₹376.60 → ₹351.90· 2025-10-30 to 2026-10-30
Charting by TradingView
This stock does not satisfy the default swing-support rules at the selected chart endpoint. Its price, volume and moving averages remain available for manual research.
Snapshot 2026-11-01 · Financial period Jun 2026 · Consolidated figures where available
Biocon Limited is an India-based biopharmaceutical company, engaged in the manufacture of biotechnology products and research services. The Company is in the business of manufacturing active pharmaceutical ingredients (APIs) and formulations, including biosimilar drugs for diabetics, oncology and autoimmune diseases. The Company’s segment includes Generics, Biosimilars, Novel Biologics and Research Services. It focuses on three key therapeutic areas - Oncology, Diabetes, and Immunology. Its APIs portfolio includes cardiovascular, anti-diabetics, immunosuppressants, and specialty molecules. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. Its APIs manufacturing facilities with capabilities in microbial fermentation, downstream process, including chromatographic purification, chemical synthesis, peptide synthesis and Highly Potent APIs (HPAPIs). It has over five facilities in Bangalore, Hyderabad and Visakhapatnam in India.
Market Cap
₹57,365.23 Cr
P/E
137.50×
Sector -38.72× · above
P/B
1.66×
Sector 4.11× · below
EV / EBITDA
20.14×
Sector 22.21× · below
ROE
1.14%
Sector 0.31%
ROCE
3.64%
Sector 6.48%
ROA
0.65%
Sector -17.12%
Cash Flow / Profit
5.41×
| Period | Revenue | Operating profit | Net profit |
|---|---|---|---|
| Jun 2026 | 4,390.5 -3.9% | 127.6 | 136.8 -31.1% |
| Mar 2026 | 4,569.1 +6.5% | 247.5 | 198.6 +483.4% |
| Dec 2025 | 4,290.3 -2.2% | -67.8 | -51.8 -139.0% |
| Sep 2025 | 4,388.5 | 171.3 | 132.8 |
Dividend
03 Jul 2026 · ₹0.5